Key points are not available for this paper at this time.
Key Points Clofarabine integrated in standard induction therapy for newly diagnosed AML reduces relapse probability but does not improve survival. Clofarabine improves survival in intermediate-risk AML categories ELN-1 and the AML genotype without NPM1 and without FLT3-ITD gene mutations.
Löwenberg et al. (Wed,) studied this question.